SillaJen to Conduct Small-Scale Merger with Woosung Pharmaceutical

On April 24, SillaJen announced that it will merge with its subsidiary, Woosung Pharmaceutical, through an absorption-type merger. The company explained that the decision was made to "enhance management efficiency and create synergy." The merger will be conducted as a small-scale merger. SillaJen will remain as the surviving company, while Woosung Pharmaceutical will be dissolved after the merger. The merger ratio between SillaJen and Woosung Pharmaceutical is 1 to 0, and no new shares will be issued upon the merger. The effective date of the merger is July 1, 2025.

This content was produced with the assistance of AI translation services.